Events & Presentations

Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Archives

Date Event Details
Feb 16, 2017
11:45 AM ET
2nd Annual Disruptive Growth & Healthcare Conference
Jan 19–21, 2017
ASCO Genitourinary Cancers Symposium - San Francisco, CA

Title: RX3117, An Oral Antimetabolite Nucleoside Shows Activity in Subjects with Pancreatic Cancer. Preliminary Results of Stage 1 of the Phase 1a/2b Study [View Poster]

Jan 10, 2017
8:30 AM PT
The 9th Annual Biotech Showcase™ 2017 conference
Oct 7–11, 2016
ESMO 2016 Congress From disease treatment to patient care

Title: RX-3117, An Oral Antimetabolite to Treat Advanced Solid Tumors (ST): Phase 1 and Ongoing Phase 2a Results

[View Poster]

Title: Phase 1/2a Study of RX-5902 in Advanced Solid Tumors (ST): an Orally Bioavailable Inhibitor of Phosphorylated p68 and Modulator of β-Catenin Nuclear Translocation

[View Poster]

Sep 12, 2016
11:15 AM ET
The 18th Annual Rodman & Renshaw Global Investment Conference
Jun 3–7, 2016
2016 American Society of Clinical Oncology Annual Meeting

Title: Results of a Phase 1 Study of Single Agent RX-3117, An Oral Metabolite Nucleoside to Treat Solid Tumors.
[View Poster]

Title: Results of a Phase 1 Study of RX-5902, An Orally Available Inhibitor of Phosphorylated P68, Targeting Solid Tumors.

[View Poster]

Title: Results from a Phase 1b/2 Study of RX-0201, A Novel AKT-1 Antisense, Combined with Everolimus to Treat Metastatic Clear Cell Renal Carcinoma.
[View Poster]

Apr 16–20, 2016
American Association for Cancer Research (AACR) 107th Annual Meeting

Title: Phase Ib/II Study of RX-0201, a Novel AKT-1 Antisense Combined with Everolimus to Treat Metastatic Renal Cell Carcinoma – Phase Ib Results.
[View Poster]

Title: Folate Receptor-Targeted Lipid Coated Albumin Nanoparticles (F-LCAN) for Therapeutic Delivery of RX-0201 (Archexin®), an Antisense Oligonucleotide Against AKT-1.
[View Poster]

Title: Inhibition of DNA Methyltransferase by RX-3117 Leads to Upregulation of Hypomethylated Targets.
[View Poster]

 

Mar 21–23, 2016
14th Annual Targeted Anticancer Therapeutics Congress (TAT 2016)
Location: Washington, DC

Title: Novel Targeted Phosphorylated p68 Inhibitor RX-5902 Shows Activity in Triple-Negative Breast Cancer Presentation .
[View Presentation]

Feb 8–9, 2016
18th Annual BIO CEO Investor Conference
Location: New York, NY
Jan 21–23, 2016
ASCO Gastrointestinal Cancers Symposium

Title: RX-5902 a Phosphorylated p68 Targeting Agent to Treat Subjects with Advanced Solid Tumors.
[View Poster]

Title: The Anticancer Effects of Supinoxin (RX-5902) in Pancreatic Cancer.
[View Poster]

Jan 11, 2016
4:30 PM PT
8th Annual Biotech Showcase Investor Conference 2016
Location: San Francisco, CA
Jan 7–9, 2016
ASCO Genitourinary Cancers Symposium
Location: San Francisco, CA

Title: Archexin, A Novel AKT-1 Specific Inhibitor for the Treatment of Metastatic Renal Cancer – Preliminary Stage 1 Data.
[View Poster]

Title: The Anticancer Effects of Supinoxin(RX-5902) in Renal Cell Cancer.
[View Poster]

Dec 8–10, 2015
The 38th Annual San Antonio Breast Cancer Symposium
Location: San Antonio, Texas

Title: New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer.
[View Poster]

Nov 17–18, 2015
Stifel 2015 Healthcare Conference
Location: New York, NY
Nov 6–7, 2015
14th Annual Kidney Cancer Symposium
Location: Miami, FL

Title: RX-0201, An Anti-Sense Targeting AKT-1 to Treat Metastatic Renal Cancer - Preliminary Stage 1 Data.
[View Poster]

Oct 20, 2015
2:30 PM PT
14th Annual BIO Investor Forum
Location: San Francisco, CA
Sep 27, 2015
The 18th ECCO – 40th ESMO European Cancer Congress 2015

Title: Single Agent Supinoxin Targeting Phosphorylated p-68, Preliminary Phase I Data.
[View Poster]

Title: Preliminary Phase I Data of Single Agent RX-3117, an Oral Antimetabolite Nucleoside.

[View Poster]

Sep 16, 2015
1:45 PM ET
The BioPharm America™ 2015 Conference
Sep 10, 2015
11:40 AM ET
17th Annual Rodman & Renshaw Global Investment Conference
Location: New York, NY
May 29–Jun 2, 2015
The 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Title: A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors.
[View Poster]

Title: A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors.
[View Poster]

Title: A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the safety and efficacy of RX-0201 in combination with everolimus to treat subjects with advanced renal cell carcinoma.
 [View Poster]

Title: A phase 1 exploratory study of RX-3117 to determine oral bioavailability in cancer subjects with solid tumors.
[View Abstract]

Apr 18–22, 2015
American Association for Cancer Research (AACR) 106th Annual Meeting

Title: Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker
 [View Poster]

Title: Targeting localization and function of the RNA helicase DDX5/p68 With 1-(3,5-imethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)
 [View Poster]

 

Mar 9, 2015
ROTH Capital Partners 27th Annual Growth Stock Conference
Feb 10, 2015
2015 BIO CEO & Investor Conference
Jan 14, 2015
The Seventh Annual Biotech Showcase™ Investor Conference
Dec 10, 2014
Oppenheimer & Co. Inc. 25th Annual Healthcare Conference
Nov 18, 2014
The Stifel 2014 Healthcare Conference
Oct 7, 2014
The 13th Annual BIO Investor Forum
Sep 9, 2014
The 16th Annual Rodman & Renshaw Global Investment Conference
Apr 5–9, 2014
American Association for Cancer Research (AACR) 105th Annual Meeting

Title: A novel small molecule cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to treatment with gemcitabine
 [View Poster]

Title: Synthesis of targeted docetaxel-polymer conjugate and its anti-tumor efficacy
 [View Poster]

 

Mar 11, 2014
The 26th Annual ROTH Conference
Feb 10, 2014
Rexahn Pharmaceuticals presentation from the 2014 BIO CEO & Investor Conference
Jan 14, 2014
Rexahn Pharmaceuticals at Biotech Showcase 2014
Sep 9, 2013
Rodman & Renshaw Annual Global Investment Conference
Apr 22–25, 2013
2013 BIO International Convention in Chicago, Illinois
Apr 6–10, 2013
American Association for Cancer Research (AACR) 104th Annual Meeting

Title: Mechanistic study of a new 4-(3, 5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide compound (RX-5902)
 [View Poster]

Mar 17–20, 2013
25th Annual ROTH Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, CA.
Add to Briefcase = add file to Briefcase


©2017 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy